Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Barriers to receiving CAR T-cell treatment among patients with non-Hodgkin lymphoma who were deemed eligible for CAR T-cell therapy

Andrew Park, Selin Cooper, Sheila Mpima, Vicky Casey, Ângela Nunes, Fil Manuguid

Blood (2025) 146 (Supplement 1): 2721.

https://doi.org/10.1182/blood-2025-2721

Published: 2025

Journal Articles

Number of cardiac deaths associated with ibrutinib versus zanubrutinib for the treatment of chronic lymphocytic leukemia: A European risk-based estimation

Talha Munir, Paolo Sportoletti, Andrea Visentin, Leyla Mohseninejad, Lianne Barnieh, Keri Yang, Wassim Aldairy, Sheila Mpima, Vicky Casey, Rhys Williams, Raul Diez Fernandez, Francisco Javier Diaz Galvez, Vincent Levy

Blood (2025) 146 (Supplement 1): 8033.

https://doi.org/10.1182/blood-2025-8033

Published: 2025

Journal Articles

Patient Characteristics and Treatment Patterns for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) By CAR T Eligibility and Treatment Status in France, Germany, Italy, Spain, the UK, and Japan

Andrew Park, Selin Cooper, Sheila Mpima, Vicky Casey, Moulika Chatu, Ângela Nunes, Fil Manuguid, Alexander Liede

Blood (2024) 144 (Supplement 1): 3723.

https://doi.org/10.1182/blood-2024-199788

Published: 2024

Journal Articles

Uptake of Novel Therapies into First-Line Treatment for AML Patients - EU5 Perspective

Thomas Moehler, MD PhD, Magdalena Ruiz, MD MSc, Vicky Casey, Luana Margotto Soares, Fil Manuguid, Kriti Jindal, MS, Sari Heitner Enschede, MD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-135921

Published: 2020

Journal Articles

Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children’s Oncology Group Study.

Robert P. Castleberry, MD, Mignon L. Loh, MD, Nalini Jayaprakash, April Peterson, Vicky Casey, Myron Chang, PhD, Brigitte Widemann, MD, Peter D. Emanuel, MD

Blood (2005) 106 (11): 2587.

https://doi.org/10.1182/blood.V106.11.2587.2587

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Barriers to receiving CAR T-cell treatment among patients with non-Hodgkin lymphoma who were deemed eligible for CAR T-cell therapy

Number of cardiac deaths associated with ibrutinib versus zanubrutinib for the treatment of chronic lymphocytic leukemia: A European risk-based estimation

Patient Characteristics and Treatment Patterns for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) By CAR T Eligibility and Treatment Status in France, Germany, Italy, Spain, the UK, and Japan

Uptake of Novel Therapies into First-Line Treatment for AML Patients - EU5 Perspective

Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children’s Oncology Group Study.

Email alerts

ASH Publications

American Society of Hematology

Update search

Barriers to receiving CAR T-cell treatment among patients with non-Hodgkin lymphoma who were deemed eligible for CAR T-cell therapy

Number of cardiac deaths associated with ibrutinib versus zanubrutinib for the treatment of chronic lymphocytic leukemia: A European risk-based estimation

Patient Characteristics and Treatment Patterns for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) By CAR T Eligibility and Treatment Status in France, Germany, Italy, Spain, the UK, and Japan

Uptake of Novel Therapies into First-Line Treatment for AML Patients - EU5 Perspective

Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children’s Oncology Group Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only